Erasca Faces Class Action Lawsuit, Investors Urged to Lead
Investors who experienced substantial losses in Erasca, Inc. stock are being called upon to lead a class action lawsuit against the company. The deadline to seek appointment as lead plaintiff is August 10, 2026.
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Erasca, Inc., a clinical-stage precision oncology company. The lawsuit alleges violations of the Securities Exchange Act of 1934, charging Erasca and certain executive officers with making false and misleading statements. Investors who purchased or acquired Erasca common stock between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff.
The core of the allegations centers on Erasca's drug candidate, ERAS-0015. The lawsuit claims that preclinical data for ERAS-0015 was improperly compared to competitor Revolution Medicines, Inc., potentially infringing on patent and trade secret protections. Investors contend that Erasca lacked a reasonable basis for its positive statements regarding ERAS-0015 due to these issues.
Erasca's stock price experienced significant drops following disclosures in late April 2026. The company received a letter from Revolution Medicines asserting patent infringement and trade secret misappropriation related to ERAS-0015, causing an initial stock decline. Subsequently, Erasca reported preliminary Phase I data for ERAS-0015, including a patient death, and acknowledged limitations in comparing its data to other studies, leading to a further substantial drop in its share price.
The Private Securities Litigation Reform Act allows investors with substantial losses during the specified class period to seek lead plaintiff status. The lead plaintiff plays a key role in directing the lawsuit. An investor's ability to share in any potential recovery is not contingent on serving as lead plaintiff.